The Pharmacist's Role in Management of CLL Treatment

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, discusses the importance of the pharmacist's role in the management of chronic lymphocytic leukemia treatments.


Huge role for pharmacists, no matter where pharmacists practice. Some of the things could be toxicity management, helping with financial access, and actually helping with adherence to some of the therapies. We’re learning from some of the landmark trial data from the RESONATE trial with ibrutinib that adherence really does matter, as we found out in CML literature. So greater than 90% adherence really does lend towards better outcomes. Certainly helping with infection prophylaxis for some of these newer therapies, and as patients are receiving different therapies over time, considering that infection risk at a patient-specific level.

To learn more, watch our Peer Exchange series on patient accessibility for oral oncolytics in CLL



Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.